CLINICAL_TRIALS
trial_result
· 2019-02-26
Clinical Trial Update: A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors [Phase 2]
Summary
Phase II study of sirolimus and erlotinib in relapsed/recurrent germ cell tumors was terminated; results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Theodore Laetsch | Conditions: Relapsed / Recurrent Germ Cell Tumors | Phase 2 | Status: TERMINATED | Results posted: 2019-02-26